Catalyst Pharma (CPRX) Stock Statistics & Valuation Metrics

Catalyst Pharma has a market cap or net worth of $2.61B. The enterprise value is $2.12B.

Catalyst Pharma has 121.45M shares outstanding. The number of shares has decreased by -2.65% in one year.

Catalyst Pharma’s return on equity (ROE) is 0.23 and return on invested capital (ROIC) is 20.24%.

The current PE Ratio of Catalyst Pharma is 15.08. Catalyst Pharma’s PEG ratio is 0.14.

In the last 12 months, Catalyst Pharma had revenue of $491.73M and earned $163.89M in profits. Earnings per share was $1.39.

In the last 12 months, operating cash flow was $239.81M and capital expenditures -$556.00K, giving a free cash flow of $239.25M billion.

Catalyst Pharma pays an annual dividend of , resulting in a dividend yield of

Catalyst Pharma upcoming earnings date is May 7, 2025, After Close.

Catalyst Pharma as a current ratio of 5.17, with Debt / Equity ratio of <0.01

In the past 12 months, Catalyst Pharma has paid $52.37M in taxes.

Catalyst Pharma EV to EBITDA ratio is 10.03, with an EV/FCF ratio of 13.65.

Catalyst Pharma has $517.55M in cash and marketable securities with $3.19M in debt, giving a net cash position of -$514.37M billion.

Gross margin is 86.00%, with operating margin of 39.68%, and net profit margin of 33.33%.

The average price target for Catalyst Pharma is $34.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy